| scholarly article | Q13442814 |
| P50 | author | Parasuram Krishnamoorthy | Q55446083 |
| Joel M Gelfand | Q60659843 | ||
| P2093 | author name string | Nehal N Mehta | |
| Lifeng Zhang | |||
| Emile R Mohler | |||
| Wade T Rogers | |||
| Junko Takeshita | |||
| Jonni Moore | |||
| P2860 | cites work | Bioconductor: open software development for computational biology and bioinformatics | Q21194861 |
| flowCore: a Bioconductor package for high throughput flow cytometry | Q33428799 | ||
| Proteomics, metabolomics, and immunomics on microparticles derived from human atherosclerotic plaques | Q33520612 | ||
| The risk of stroke in patients with psoriasis | Q33831094 | ||
| Patients with severe psoriasis are at increased risk of cardiovascular mortality: cohort study using the General Practice Research Database | Q33951592 | ||
| Microparticles in cardiovascular diseases. | Q34221054 | ||
| Psoriasis and the risk of diabetes mellitus: a systematic review and meta-analysis | Q34327755 | ||
| Attributable risk estimate of severe psoriasis on major cardiovascular events | Q35135113 | ||
| Systemic and vascular inflammation in patients with moderate to severe psoriasis as measured by [18F]-fluorodeoxyglucose positron emission tomography-computed tomography (FDG-PET/CT): a pilot study | Q35171276 | ||
| Monocytic microparticles activate endothelial cells in an IL-1β-dependent manner | Q35182740 | ||
| Endothelial microparticles: sophisticated vesicles modulating vascular function | Q35624092 | ||
| Prevalence of metabolic syndrome in patients with psoriasis: a population-based study in the United Kingdom | Q35753936 | ||
| PECAM-1 is required for transendothelial migration of leukocytes | Q36362038 | ||
| Personalized cytomic assessment of vascular health: Evaluation of the vascular health profile in diabetes mellitus | Q37267758 | ||
| Endothelial microparticles in diseases | Q37319478 | ||
| Endothelial progenitor cells: novel players in the pathogenesis of rheumatic diseases | Q37624581 | ||
| The role of microparticles in the pathogenesis of rheumatic diseases. | Q37641758 | ||
| Circulating microparticles in cardiovascular disease: implications for atherogenesis and atherothrombosis | Q37778858 | ||
| Microparticles as regulators of cardiovascular inflammation | Q38032036 | ||
| The association between psoriasis and dyslipidaemia: a systematic review | Q38056160 | ||
| The association between psoriasis and obesity: a systematic review and meta-analysis of observational studies | Q38064779 | ||
| Circulating CD31+/Annexin V+ microparticles correlate with cardiovascular outcomes | Q43472325 | ||
| Circulating microparticles from patients with myocardial infarction cause endothelial dysfunction. | Q43808880 | ||
| CD40 ligand+ microparticles from human atherosclerotic plaques stimulate endothelial proliferation and angiogenesis a potential mechanism for intraplaque neovascularization | Q45009308 | ||
| Increased levels of circulating endothelial-derived microparticles and small-size platelet-derived microparticles in psoriasis. | Q47386155 | ||
| Psoriasis | Q56115292 | ||
| Expression of coagulant activity in human platelets: Release of membranous vesicles providing platelet factor 1 and platelet factor 3 | Q57977248 | ||
| Microparticles From Human Atherosclerotic Plaques Promote Endothelial ICAM-1–Dependent Monocyte Adhesion and Transendothelial Migration | Q60621574 | ||
| Risk of Myocardial Infarction in Patients With Psoriasis | Q60711909 | ||
| Plasmatic Level of Leukocyte-Derived Microparticles Is Associated With Unstable Plaque in Asymptomatic Patients With High-Grade Carotid Stenosis | Q62606094 | ||
| Molecular and functional aspects of PECAM-1/CD31 | Q72768308 | ||
| Platelet microparticles promote platelet interaction with subendothelial matrix in a glycoprotein IIb/IIIa-dependent mechanism | Q77756614 | ||
| Platelet activation in patients with psoriasis: increased plasma levels of platelet-derived microparticles and soluble P-selectin | Q84984143 | ||
| P433 | issue | 1 | |
| P921 | main subject | endothelium | Q111140 |
| macrophage | Q184204 | ||
| P304 | page(s) | e000507 | |
| P577 | publication date | 2014-02-28 | |
| P1433 | published in | Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease | Q19880670 |
| P1476 | title | Endothelial cell-, platelet-, and monocyte/macrophage-derived microparticles are elevated in psoriasis beyond cardiometabolic risk factors | |
| P478 | volume | 3 |
| Q89843976 | A Randomized Placebo Controlled Trial of Secukinumab on Aortic Vascular Inflammation in Moderate to Severe Plaque Psoriasis (VIP-S) |
| Q48280242 | Applicability of extracellular vesicles in clinical studies. |
| Q34626474 | Circulating extracellular vesicles with specific proteome and liver microRNAs are potential biomarkers for liver injury in experimental fatty liver disease |
| Q58719835 | Extracellular Vesicles as Biomarkers in Cardiovascular Disease; Chances and Risks |
| Q99419055 | Extracellular vesicles in Inflammatory Skin Disorders: from Pathophysiology to Treatment |
| Q50319342 | Flow analysis of individual blood extracellular vesicles in acute coronary syndrome |
| Q42363103 | Increased levels of circulating platelet-derived microparticles in psoriasis: Possible implications for the associated cardiovascular risk |
| Q33645863 | Long-term treatment of chronic plaque psoriasis with biological drugs can control platelet activation: targeting the bridge between inflammation and atherothrombosis |
| Q44306337 | M2 Monocyte Microparticles Are Increased in Intracerebral Hemorrhage |
| Q37700810 | Microglial-derived microparticles mediate neuroinflammation after traumatic brain injury. |
| Q36816361 | Microparticles as novel biomarkers and therapeutic targets in coronary heart disease |
| Q99202044 | National Psoriasis Foundation COVID-19 Task Force Guidance for Management of Psoriatic Disease During the Pandemic: Version 1 |
| Q36828238 | No Significant Reduction of Circulating Endothelial-Derived and Platelet-Derived Microparticles in Patients with Psoriasis Successfully Treated with Anti-IL12/23 |
| Q90248096 | Pathogenesis of Chronic Plaque Psoriasis and Its Intersection With Cardio-Metabolic Comorbidities |
| Q46180528 | Psoriasis and Cardiovascular Comorbidities: Focusing on Severe Vascular Events, Cardiovascular Risk Factors and Implications for Treatment |
| Q30235889 | Psoriasis and comorbid diseases: Epidemiology |
| Q38842491 | Review: the Multiple Roles of Monocytic Microparticles |
| Q38819355 | Risk of venous thromboembolism in patients with psoriatic arthritis, psoriasis and rheumatoid arthritis: a general population-based cohort study. |
| Q45967235 | Technological Advances in Cardiovascular Safety Assessment Decrease Preclinical Animal Use and Improve Clinical Relevance. |
| Q94070955 | The Role of Microparticles in Rheumatic Diseases and their Potentials as Therapeutic Tools |
| Q47644680 | The impact of biologic agents on health-related quality of life outcomes in patients with psoriasis |
| Q30250110 | Updates on cardiovascular comorbidities associated with psoriatic diseases: epidemiology and mechanisms |
Search more.